ArticleAnnals of the rheumatic diseases2006

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

A Boonen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.